EMA Authorised: Bomyntra (denosumab) — Fresenius Kabi Deutschland GmbH

View source ↗

Summary

Bomyntra (denosumab) has been authorised by the EMA for indications related to bone neoplasms including Giant Cell Tumor of Bone; MAH is Fresenius Kabi Deutschl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Neoplasms
• Giant Cell Tumor of Bone

Drugs mentioned

• Bomyntra (denosumab)

Snippet

Status: Authorised. Therapeutic area: Neoplasms, Bone Tissue;Giant Cell Tumor of Bone. MAH: Fresenius Kabi Deutschland GmbH. Decision date: 21/08/2026